Bio-Rad Labs (BIO) Tops Q1 EPS by 30c

Bio-Rad Labs (NYSE: BIO) reported Q1 EPS of $1.91, $0.30 better than the analyst estimate of $1.61. Revenue for the quarter came in at $571.6 million versus the consensus estimate of $554.89 million.

2020 Financial Outlook

Given the uncertainties regarding the duration and impact of the COVID-19 pandemic, we are withdrawing our previously issued annual guidance for this year. We believe our second-quarter year-over-year sales may decline by 10 to 15 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
• Netflix gains after Ackman endorsement and AI feature launch
• Stifel Positive on Rapport Therapeutics (RAPP): 'remains on track to share longer-term safety data from the ph2a in 4Q26'